Rapport Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Operating income | -$125.1 | -$83.1 | -$36.2 | — |
| Net income | -$111.5 | -$78.3 | -$34.8 | — |
| Cash Flow Statement | ||||
| Free cash flow | -$88.1 | -$67.2 | -$28.8 | — |
| Share repurchases | $<0.1 | — | $<0.1 | — |
Shares outstanding 48.0M · Free float 60.2%
Annual filing data through FY ended December 31, 2025; float as of October 6, 2026.